A Phase II, Open-Label, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in Subjects With Steroid-Refractory Chronic Graft-versus-Host Disease.
Phase of Trial: Phase II
Latest Information Update: 12 Aug 2013
At a glance
- Drugs Alefacept (Primary) ; Alefacept (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 24 Jan 2012 Planned End Date changed from 1 Sep 2012 to 1 Jan 2013 as reported by ClinicalTrials.gov.
- 24 Jan 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 28 Oct 2010 New trial record